Sean Lavin

Sean Lavin M.D. began his Wall Street career as an equity research analyst at Oppenheimer and Co in 2006. He then transitioned to Lazard Capital Markets, before helping build the healthcare group as a Senior Research Analyst covering Medical Devices, Diagnostics, and Digital Health companies at BTIG. Sean left BTIG at the end of 2019 to form his own advisory firm, Alpha Lavin Advisors, LLC. Over the past 14 years, Sean supplied some of the most sought after research advice in these sectors to approximately 1000 institutional investment funds. He covered approximately fifty public companies during this time period and helped BTIG be involved in ~$25B in new capital raises for healthcare companies over the past five years. ~$14B of this went to device and diagnostic companies, which were Sean's lead areas of focus. Details on these capital raises can be found here.

Before beginning his successful Wall Street career, Sean graduated from the Massachusetts Institute of Technology (MIT) with a B.S. in Chemistry, Minor in Biology, and Concentration in Economics. Sean then earned his M.D. from the Ohio State University College of Medicine. He then spent several years as a surgical resident in Miami, FL that involved Mt. Sinai Medical Center, Hollywood Memorial Hospital, and Jackson Memorial Hospital. During these years, Sean spent time training in general surgery, urology, trauma surgery, plastic and reconstructive surgery, transplant surgery, oncologic surgery, the ICU, and emergency medicine. The things he learned as a clinician prove invaluable in identifying devices and technologies that he feels will be embraced and rapidly adopted by physicians. Glen holds Series 7, 63, 79, 86, 87 and 24 securities licenses. Sean holds Series 7, 63, 86, and 87 and securities licenses.

Away from work, Sean is an avid skier having raced for years, enjoys world travel, live music, craft beer, red wine, observing many sports, and photography, and is becoming a collector of modern art.

Deal Interest: Capital raises $10M-$100M, Strategic consulting, and M&A in Medical Devices, Diagnostics, and Digital Health.